Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis
Zenner HP, Baumgarten C, Rasp G, Fuchs T, Kunkel G, Hauswald B, Ring J, Effendy I, Behrendt W, Frosch PJ, Przybilla B, et al. (1997)
Journal of Allergy and Clinical Immunology 100(1): 23-29.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Zenner, HP;
Baumgarten, C;
Rasp, G;
Fuchs, T;
Kunkel, G;
Hauswald, B;
Ring, J;
Effendy, IsaakUniBi ;
Behrendt, W;
Frosch, PJ;
Przybilla, B;
Brunner, FX
Alle
Alle
Abstract / Bemerkung
Background: Short-term immunotherapy (STI) can be beneficial for patients who are noncompliant,vith long-term specific immunotherapy. Objective: The efficacy and tolerance of STI with seven pre-seasonal injections of molecular standardized allergens from grass and rye pollen has been investigated in a double-blind, placebo-controlled multicenter study with 87 patients at 12 German University hospitals. Methods: Symptoms of the eyes, nose, and bronchi and use of symptomatic drugs were documented daily in diaries by patients with allergic rhinitis to grass and/or rye pollen and without bronchial asthma. Patients were monitored by skin prick test titration and measurement of levels of specific IgE and IgG4. Results: The median nasal score for the 10 weeks with the strongest symptoms during the gross pollen season was significantly lower (p = 0.014) with 35.0 for STI (n = 41) versus 69.0 for placebo (n = 40); the overall symptom score was 54.0 for STI versus 97.5 for placebo (p = 0.020). Only STI-treated patients exposed to less than 40 pollen grains per cubic meter per week showed a significantly lower nasal symptom score of 39.0 versus 75.0 for placebo (p = 0.006); these patients also had fewer nasal symptoms and less use of topical nasal drugs (p < 0.001). The threshold dose in skin prick tests was significantly higher, being 9.06 histamine equivalent for skin prick test (HEP) for STI-treated patients who received the maximum dose (n = 22) versus 4.33 HEP for placebo (p = 0.005). Specific IgE levels were significantly higher, being 55.9 SU/ml for STI versus 393 SU/ml for placebo after seven injections (p = 0.006) and level of specific IgG4 was 5.36% for STI versus 1.28% for placebo (p < 0.001). No severe systemic reactions were observed. Conclusion: Sn with seven preseasonal injections with molecular standardized allergens is effective and well tolerated.
Stichworte
short-term immunotherapy;
specific immunotherapy;
allergic rhinitis;
grass pollen;
rye pollen;
skin prick rest;
specific IgE;
specific IgG4
Erscheinungsjahr
1997
Zeitschriftentitel
Journal of Allergy and Clinical Immunology
Band
100
Ausgabe
1
Seite(n)
23-29
ISSN
0091-6749
Page URI
https://pub.uni-bielefeld.de/record/2968822
Zitieren
Zenner HP, Baumgarten C, Rasp G, et al. Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. Journal of Allergy and Clinical Immunology. 1997;100(1):23-29.
Zenner, H. P., Baumgarten, C., Rasp, G., Fuchs, T., Kunkel, G., Hauswald, B., Ring, J., et al. (1997). Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. Journal of Allergy and Clinical Immunology, 100(1), 23-29. https://doi.org/10.1016/S0091-6749(97)70190-8
Zenner, HP, Baumgarten, C, Rasp, G, Fuchs, T, Kunkel, G, Hauswald, B, Ring, J, et al. 1997. “Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis”. Journal of Allergy and Clinical Immunology 100 (1): 23-29.
Zenner, H. P., Baumgarten, C., Rasp, G., Fuchs, T., Kunkel, G., Hauswald, B., Ring, J., Effendy, I., Behrendt, W., Frosch, P. J., et al. (1997). Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. Journal of Allergy and Clinical Immunology 100, 23-29.
Zenner, H.P., et al., 1997. Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. Journal of Allergy and Clinical Immunology, 100(1), p 23-29.
H.P. Zenner, et al., “Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis”, Journal of Allergy and Clinical Immunology, vol. 100, 1997, pp. 23-29.
Zenner, H.P., Baumgarten, C., Rasp, G., Fuchs, T., Kunkel, G., Hauswald, B., Ring, J., Effendy, I., Behrendt, W., Frosch, P.J., Przybilla, B., Brunner, F.X., Merk, H.F., Kapp, A., Schnitker, J., Wolf, H.: Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. Journal of Allergy and Clinical Immunology. 100, 23-29 (1997).
Zenner, HP, Baumgarten, C, Rasp, G, Fuchs, T, Kunkel, G, Hauswald, B, Ring, J, Effendy, Isaak, Behrendt, W, Frosch, PJ, Przybilla, B, Brunner, FX, Merk, HF, Kapp, A, Schnitker, J, and Wolf, H. “Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis”. Journal of Allergy and Clinical Immunology 100.1 (1997): 23-29.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
References
Daten bereitgestellt von Europe PubMed Central.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 9257783
PubMed | Europe PMC
Suchen in